Cefotaxime and Inflammatory marker increased - a phase IV clinical study of FDA data

Summary:

Inflammatory marker increased is reported as a side effect among people who take Cefotaxime (cefotaxime sodium), especially for people who are male, 2-9 old, have been taking the drug for < 1 month also take Vancomycin, and have Pantoea agglomerans infection.

The phase IV clinical study analyzes which people have Inflammatory marker increased when taking Cefotaxime. It is created by eHealthMe based on reports of 7,540 people who have side effects when taking Cefotaxime from the FDA, and is updated regularly.

What is Cefotaxime?

Cefotaxime has active ingredients of cefotaxime sodium. eHealthMe is studying from 7,559 Cefotaxime users. Check the latest studies of Cefotaxime.

What is Inflammatory marker increased?

Inflammatory marker increased is found to be associated with 395 drugs and 391 conditions by eHealthMe. Check the latest studies of Inflammatory marker increased.

On Jul, 16, 2026

7,540 people reported to have side effects when taking Cefotaxime.
Among them, 32 people (0.42%) have Inflammatory marker increased.

Could Cefotaxime cause Inflammatory marker increased?

Among these 32 people:

How long have people been on Cefotaxime when they have Inflammatory marker increased? *

What is the gender of people who have Inflammatory marker increased when taking Cefotaxime? *

female: 8.33 %
male: 91.67 %

What is the age of people who have Inflammatory marker increased when taking Cefotaxime? *

What are other drugs people take besides Cefotaxime? *

What are other side effects people have besides Inflammatory marker increased? *

Fever: 21 people, 65.62%
Leukocytosis (increased white blood cells): 17 people, 53.12%
Drug Ineffective: 10 people, 31.25%
Sepsis (a severe blood infection that can lead to organ failure and death): 10 people, 31.25%
Hepatosplenomegaly Neonatal (enlargement of both the liver and the spleen in neonatal): 9 people, 28.12%
Fever Neonatal: 9 people, 28.12%
Pantoea Agglomerans Infection (pantoea agglomerans is a gram-negative bacterium that belongs to the family enterobacteriaceae causing wound, blood, and urinary-tract infections): 9 people, 28.12%
Pleocytosis (increased cell count): 9 people, 28.12%
Respiratory Disorder Neonatal (disease of respiratory organs in a month old baby): 9 people, 28.12%
Thrombocytopenia Neonatal (decrease of platelets in blood in baby less than a month): 9 people, 28.12%

What are the existing conditions these people have? *

Pantoea Agglomerans Infection (pantoea agglomerans is a gram-negative bacterium that belongs to the family enterobacteriaceae causing wound, blood, and urinary-tract infections): 9 people, 28.12%
Ruptured Eardrum (tear in eardrum): 7 people, 21.88%
Otitis Media Acute (rapid inflammation of the middle ear): 7 people, 21.88%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 5 people, 15.62%
Meningitis Streptococcal (a bacterial infection of the membranes covering the brain and spinal cord (meninges)): 4 people, 12.50%
Urination - Excessive Volume: 1 person, 3.12%
Sinusitis Bacterial (bacterial infection of sinus): 1 person, 3.12%
Osteomyelitis Bacterial (infection of bone by bacteria): 1 person, 3.12%
Meningism (the triad of nuchal rigidity (neck stiffness), photophobia (intolerance of bright light) and headache. it is a sign of irritation of the meninges): 1 person, 3.12%
Immunodeficiency Disorders: 1 person, 3.12%

* Approximation only. Some reports may have incomplete information.

Do you take Cefotaxime and have Inflammatory marker increased?

- Check whether Inflammatory marker increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cefotaxime:

Cefotaxime (7,559 reports)

Browse all side effects of Cefotaxime:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Inflammatory marker increased:

Inflammatory marker increased (396 drugs)

Browse all the conditions that are associated with Inflammatory marker increased:

Inflammatory marker increased (391 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on cefotaxime sodium (the active ingredients of Cefotaxime) and Cefotaxime (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.